IN8bio Inc INAB.OQ INAB.O is expected to show no change in quarterly revenue when it reports results on November 3 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for IN8bio Inc is for a loss of $1.23 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for IN8bio Inc is $7.00, about 71.6% above its last closing price of $1.99
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -1.68 | -1.80 | -1.24 | Beat | 31.1 |
Mar. 31 2025 | -2.00 | -2.00 | -2.10 | Missed | -5 |
Dec. 31 2024 | -2.45 | -2.25 | -1.20 | Beat | 46.7 |
Sep. 30 2024 | -4.99 | -4.80 | -4.50 | Beat | 6.3 |
Jun. 30 2024 | -5.23 | -5.04 | -5.70 | Missed | -13.1 |
Mar. 31 2024 | -5.26 | -5.32 | -6.00 | Missed | -12.7 |
Dec. 31 2023 | -4.68 | -4.60 | -6.30 | Missed | -37 |
Sep. 30 2023 | -7.36 | -7.35 | -6.90 | Beat | 6.1 |
This summary was machine generated October 31 at 21:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)